319 related articles for article (PubMed ID: 7521787)
1. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
2. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.
Onda K; Davis RL; Wilson CB; Hoshino T
Acta Neuropathol; 1994; 87(6):586-93. PubMed ID: 8091951
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods.
Onda K; Davis RL; Edwards MS
J Neurooncol; 1996 Aug; 29(2):129-36. PubMed ID: 8858517
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
5. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.
Cattoretti G; Becker MH; Key G; Duchrow M; Schlüter C; Galle J; Gerdes J
J Pathol; 1992 Dec; 168(4):357-63. PubMed ID: 1484317
[TBL] [Abstract][Full Text] [Related]
7. Proliferation markers in gliomas: a comparison of BUDR, KI-67, and MIB-1.
Davis RL; Onda K; Shubuya M; Lamborn K; Hoshino T
J Neurooncol; 1995; 24(1):9-12. PubMed ID: 8523082
[No Abstract] [Full Text] [Related]
8. Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues.
Hoyt JW; Gown AM; Kim DK; Berger MS
J Neurooncol; 1995; 24(2):163-9. PubMed ID: 7562003
[TBL] [Abstract][Full Text] [Related]
9. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
Heesters MA; Koudstaal J; Go KG; Molenaar WM
J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material.
Karamitopoulou E; Perentes E; Diamantis I; Maraziotis T
Acta Neuropathol; 1994; 87(1):47-54. PubMed ID: 7511316
[TBL] [Abstract][Full Text] [Related]
11. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.
Langford LA; Cooksley CS; DeMonte F
Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
13. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
15. Variability in the proliferative potential of human gliomas.
Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
[TBL] [Abstract][Full Text] [Related]
16. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.
Schröder R; Bien K; Kott R; Meyers I; Vössing R
Acta Neuropathol; 1991; 82(5):389-94. PubMed ID: 1767633
[TBL] [Abstract][Full Text] [Related]
17. Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues.
Noordzij MA; van der Kwast TH; van Steenbrugge GJ; van Weerden WM; Oomen MH; Schröder FH
Prostate; 1995 Sep; 27(3):154-9. PubMed ID: 7567694
[TBL] [Abstract][Full Text] [Related]
18. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.
Rodríguez-Pereira C; Suárez-Peñaranda JM; Vázquez-Salvado M; Sobrido MJ; Abraldes M; Barros F; Forteza J
J Neurosurg Sci; 2000 Dec; 44(4):203-9; discussion 209-10. PubMed ID: 11327289
[TBL] [Abstract][Full Text] [Related]
19. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
20. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples.
Sallinen PK; Haapasalo HK; Visakorpi T; Helén PT; Rantala IS; Isola JJ; Helin HJ
J Pathol; 1994 Dec; 174(4):275-82. PubMed ID: 7884589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
